Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Pharmacodynamics and Pharmacogenomics

Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance

Leukemia volume 15, pages 80–88 (2001)Cite this article

Abstract

The feasibility of adding both the multidrug resistance modulator cyclosporin (CsA) and granulocyte colony-stimulating factor (G-CSF) to a standard salvage regimen of idarubicin (IDA) and cytarabine was evaluated in patients with resistant or relapsed acute myeloid leukemia and myelodysplastic syndrome. Three patients received IDA 12 mg/m2/day, the next four patients 9 mg/m2/day. The dose of CsA was 16 mg/kg/day. Six patients showed Pgp expression and none MRP1 expression. Grade III or IV toxicity (CTC-NCIC criteria) was registered in six patients for gastrointestinal, two patients for cardiovascular and one patient for neurological complications. Three patients died in hypoplasia and three patients showed leukemic regrowth. Three control patients were treated with IDA 12 mg/m2/day and cytarabine, but no CsA and G-CSF. The plasma IDA and idarubicinol (ida-ol) area under the curve's of patients treated with IDA 12 mg/m2 plus CsA were higher (P < 0.05) than in controls. cellular ida concentrations were almost similar, but cellular ida-ol concentrations were significantly higher (P < 0.05) in the presence of csa than in controls. we conclude that the toxicity either with ida 12 or 9 mg/m2/day was too high. The modulating effect of CsA was mainly based on changes in plasma kinetics of IDA and ida-ol, although ida-ol cellular clearance was delayed in the presence of CsA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Wiernik PH, Dutcher JP . Clinical importance of anthracyclines in the treatment of acute myeloid leukemia Leukemia 1992 6: (Suppl. 1) 67–69

    PubMed  Google Scholar 

  2. Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C . Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion Cancer Chemother Pharmacol 1987 20: 311–315

    CAS  PubMed  Google Scholar 

  3. Workman P . Infusional anthracyclines: is slower better? If so, why? Ann Oncol 1992 3: 591–594

    CAS  PubMed  Google Scholar 

  4. Hollingshead LM, Faulds D . Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer Drugs 1991 42: 690–719

    Article  CAS  PubMed  Google Scholar 

  5. Ames MM, Spreafico E . Selected pharmacologic characteristics of idarubicin and idarubicinol Leukemia 1992 6: (Suppl. 1) 70–75

    PubMed  Google Scholar 

  6. Carella AM, Berman E, Maraone MP, Ganzina F . Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies Haematologica 1990 75: 159–169

    CAS  PubMed  Google Scholar 

  7. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L . MDR1 gene expression and treatment outcome in acute myeloid leukemia J Natl Cancer Inst 1991 83: 708–712

    Article  CAS  PubMed  Google Scholar 

  8. Booser DJ, Hortobagyi GN . Anthracycline antibiotics in cancer therapy. Focus on drug resistance Drugs 1994 47: 223–258

    Article  CAS  PubMed  Google Scholar 

  9. Hunault M, Zhou D, Delmer A, Ramond S, Viguie F, Cadiou M, Perrot JY, Levy V, Rio B, Cymbalista F, Zittoun R, Marie JP . Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment Ann Hematol 1997 74: 65–71

    Article  CAS  PubMed  Google Scholar 

  10. List AF . Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia Leukemia 1996 10: 937–942

    CAS  PubMed  Google Scholar 

  11. Nussler V, Pelka FR, Zwierzina H, Nerl C, Beckert B, Gullis E, Gieseler F, Bock S, Bartl R, Petrides PE . Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes – first experience with their reversal Ann Hematol 1994 69: (Suppl. 1) S25–S29

    Article  PubMed  Google Scholar 

  12. Boesch D, Loor F . Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents Anticancer Drugs 1994 5: 229–238

    Article  CAS  PubMed  Google Scholar 

  13. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AP . Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia Leukemia 1994 8: 2163–2168

    CAS  PubMed  Google Scholar 

  14. Hart SM, Ganeshaguru K, Scheper RJ, Prentice HG, Hoffbrand AV, Mehta AP . Expression of the human major vault protein LRP in acute myeloid leukemia Exp Hematol 1997 25: 1227–1232

    CAS  PubMed  Google Scholar 

  15. Ling V . Multidrug resistance: molecular mechanisms and clinical relevance Cancer Chemother Pharmacol 1997 40: (Suppl.) 3–8

    Article  Google Scholar 

  16. Nooter K, Burger H, Stoter G . Multidrug resistance-associated protein (MRP) in haematological malignancies Leuk Lymphoma 1996 20: 381–387

    Article  CAS  PubMed  Google Scholar 

  17. Nooter K, Stoter G . Molecular mechanisms of multidrug resistance in cancer chemotherapy Pathol Res Pract 1996 192: 768–780

    Article  CAS  PubMed  Google Scholar 

  18. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH . Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia Blood 1995 85: 186–193

    CAS  PubMed  Google Scholar 

  19. Davey MW, Hargrave RM, Davey RA . Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells Leukemia Res 1996 20: 657–664

    Article  CAS  Google Scholar 

  20. Nagasawa K, Natazuka T, Chihara K, Kitazawa F, Tsumura A, Takara K, Nomiyama M, Ohnishi N, Yokoyama T . Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells Cancer Chemother Pharmacol 1996 37: 297–304

    Article  CAS  PubMed  Google Scholar 

  21. Twentyman PR, Versantvoort CH . Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance Eur J Cancer 1996 32A: 1002–1009

    Article  CAS  PubMed  Google Scholar 

  22. Abbaszadegan MR, Foley NE, Gleason GM, Dalton WS . Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line Int J Cancer 1996 66: 506–514

    Article  CAS  PubMed  Google Scholar 

  23. Germann UA, Ford PJ, Shlyakhter D, Mason VS, Harding MW . Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP Anticancer Drugs 1997 8: 141–155

    Article  CAS  PubMed  Google Scholar 

  24. Kim WJ, Kakehi Y, Hirai M, Arao S, Hiai H, Fukumoto M, Yoshida O . Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line Jpn J Cancer Res 1995 86: 969–977

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Michieli M, Damiani D, Michelutti A, Candoni A, Masolini P, Scaggiante B, Quadrifoglio F, Baccarani M . Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833 Haematologica 1994 79: 500–507

    CAS  PubMed  Google Scholar 

  26. Hargrave RM, Davey MW, Davey RA, Kidman AD . Development of drug resistance is reduced with idarubicin relative to other anthracyclines Anticancer Drugs 1995 6: 432–437

    Article  CAS  PubMed  Google Scholar 

  27. Berman E, McBride M . Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells Blood 1992 79: 3267–3273

    CAS  PubMed  Google Scholar 

  28. Nielsen D, Maare C, Skovsgaard T . Cellular resistance to anthracyclines Gen Pharmacol 1996 27: 251–25

    Article  CAS  PubMed  Google Scholar 

  29. Ross DD, Doyle LA, Yang W, Tong Y, Cornblatt B . Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance Biochem Pharmacol 1995 50: 1673–1683

    Article  CAS  PubMed  Google Scholar 

  30. Minderman H, Linssen P, van der Lely N, Wessels J, Boezeman J, de Witte T, Haanen C . Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state Leukemia 1994 8: 382–387

    CAS  PubMed  Google Scholar 

  31. Smeets M, Raymakers R, Vierwinden G, Pennings A, Wessels H, de Witte T . Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by down-regulating multi drug resistance Blood 1999 94: 2414–2423

    CAS  PubMed  Google Scholar 

  32. Van der Lely N, de Witte T, Wessels J, Raymakers R, Muus P, Preijers F . In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity Ann Hematol 1994 68: 225–232

    Article  CAS  PubMed  Google Scholar 

  33. Vogler WR . Strategies in the treatment of acute myelogenous leukemia Leukemia Res 1992 16: 1143–1153

    Article  CAS  Google Scholar 

  34. Dombret H . Granulocytic colony-stimulating factors in the management of patients with acute myeloid leukemia Hematol Cell Ther 1996 38: 231–240

    Article  CAS  PubMed  Google Scholar 

  35. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W . Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia J Clin Oncol 1993 11: 1652–1660

    Article  CAS  PubMed  Google Scholar 

  36. de Witte T, Suciu S, Selleslag D, Labar B, Roozendaal K, Zittoun R, Ribeiro M, Kurstjens R, Hayat M, Dardenne M, Solbu G, Muus P . Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (No. 06901) of the EORTC Leukemia Cooperative Group Ann Hematol 1996 72: 119–124

    Article  CAS  PubMed  Google Scholar 

  37. Minderman H, Vanhoefer U, Toth K, Yin MB, Minderman MD, Wrzosek C, Slovak ML, Rustum YM . DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux Cytometry 1996 25: 14–20

    Article  CAS  PubMed  Google Scholar 

  38. Webb M, Raphael CL, Asbahr H, Erber WN, Meyer BF . The detection of rhodamine 123 efflux at low levels of drug resistance Br J Haematol 1996 93: 650–655

    Article  CAS  PubMed  Google Scholar 

  39. Smeets M, Raymakers R, Vierwinden G, Pennings A, van de Locht L, Wessels H, Boezeman J, de Witte T . A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity Br J Haematol 1997 96: 346–355

    Article  CAS  PubMed  Google Scholar 

  40. Den Boer ML, Zwaan CM, Pieters R, Kazemier KM, Rottier MM, Flens MJ, Scheper RJ, Veerman AJ . Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia Leukemia 1997 11: 1078–1085

    Article  CAS  PubMed  Google Scholar 

  41. Hempel G, Haberland S, Schulze WP, Mohling N, Blaschke G, Boos J . Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis J Chromatogr B Biomed Sci 1997 Appl. 698: 287–292

    Article  Google Scholar 

  42. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J . Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 1991 77: 1666–1674

    CAS  PubMed  Google Scholar 

  43. Vogler WR, Velez GE, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PL . A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study J Clin Oncol 1992 10: 1103–1111

    Article  CAS  PubMed  Google Scholar 

  44. Wiernik PH, Banks PL, Case DCJ, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB . Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 1992 79: 313–319

    CAS  PubMed  Google Scholar 

  45. Yahanda AM, Alder KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BL . Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance J Clin Oncol 1992 10: 1624–1634

    Article  CAS  PubMed  Google Scholar 

  46. Dahl GV, Lacayo NJ, Brophy N, Dunussi Joannopoulos K, Weinstein HJ, Chang M, Sikic BJ, Arceci RJ . Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia J Clin Oncol 2000 18: 1867–1875

    Article  CAS  PubMed  Google Scholar 

  47. Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM . Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study Cancer 1999 85: 358–367

    Article  CAS  PubMed  Google Scholar 

  48. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A, Mahe B, Milpied N, Janvier M, Guerci A, Rochant H, Cordonnier C, Dreyfus F, Buzyn A, Hoang NL, Stoppa AM, Gratecos N, Sadoun A, Stamatoulas A, Tilly H, Brice P, Maloisel F, Lioure B, Desablens B, Fenaux P . Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study Br J Haematol 1998 102: 1015–1024

    Article  CAS  PubMed  Google Scholar 

  49. Damiani D, Michieli M, Ermacora A, Russo D, Fanin R, Zaja F, Baraldo M, Pea F, Furlanut M, Baccarani M . Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia Leukemia 1998 12: 1236–1240

    Article  CAS  PubMed  Google Scholar 

  50. Pea F, Damiani D, Michieli M, Ermacora A, Baraldo M, Russo D, Fanin R, Baccarani M, Furlanut M . Multidrug resistance modulation in vivo: the effects of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia Eur J Clin Pharmacol 1999 55: 361–368

    Article  CAS  PubMed  Google Scholar 

  51. Schroder JK, Kasimir Bauer S, Seeber S, Scheulen ME . In vitro effects of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia J Cancer Res Clin Oncol 2000 126: 111–116

    Article  CAS  PubMed  Google Scholar 

  52. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci USA 1987 84: 7735–7738

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S . Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16 Cancer Res 1988 48: 1926–1929

    CAS  PubMed  Google Scholar 

  54. Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F, Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T . Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas Histopathology 1991 19: 131–140

    Article  CAS  PubMed  Google Scholar 

  55. Brophy NA, Marie JP, Rojas VA, Warnke RA, McFall PJ, Smith SD, Sikic BI . Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques Leukemia 1994 8: 327–335

    CAS  PubMed  Google Scholar 

  56. Bailly JD, Muller C, Jaffrezou JP, Demur C, Gassar G, Bordier C, Laurent G . Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines Leukemia 1995 9: 799–807

    CAS  PubMed  Google Scholar 

  57. Lowenberg B, Touw IP . Hematopoietic growth factors and their receptors in acute leukemia Blood 1993 81: 281–292

    CAS  PubMed  Google Scholar 

  58. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M . Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype Blood 1992 80: 2729–2734

    CAS  PubMed  Google Scholar 

  59. Vellenga E, Ostapovicz D, O'Rourke B, Griffin JD . Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation ofleukemic clonogenic cells in short-term and long-term cultures Leukemia 1987 1: 584–589

    CAS  PubMed  Google Scholar 

  60. Lowenberg B, Salem M, Delwel R . Effects of recombinant multi-CSF, GM-CSF, G-CSF and M-CSF on the proliferation and maturation of human AML in vitro Blood Cells 1988 14: 539–549

    CAS  PubMed  Google Scholar 

  61. Visani G, Manfroi S . G-CSF in the biology and treatment of acute myeloid leukemias Leuk Lymphoma 1995 18: 423–428

    Article  CAS  PubMed  Google Scholar 

  62. Van der Lely N, de Witte T, Wessels J, Raymakers R, Muus P, Preijers F . In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity Ann Hematol 1994 68: 225–232

    Article  CAS  PubMed  Google Scholar 

  63. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Satio Y . A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group Blood 1994 83: 2086–2092

    CAS  PubMed  Google Scholar 

  64. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH . A randomized placebo-controlled phase III study of granulocyte–macrophage colony-stimulating factor in adult patients (&gt;55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490) Blood 1995 86: 457–462

    CAS  PubMed  Google Scholar 

  65. Usuki K, Iki S, Endo M, Kitazume K, Ito K, Watanabe M, Urabe A . Granulocyte colony-stimulating factor in acute myeloid leukemia Stem Cells Dayt 1995 13: 647–654

    Article  CAS  PubMed  Google Scholar 

  66. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL . Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar) Blood 1999 93: 787–795

    CAS  PubMed  Google Scholar 

  67. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M . Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia J Clin Oncol 1997 15: 1796–1802

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Ank van Vlissingen Foundation, The Netherlands and the Bekalis Foundation, Belgium.

Author information

Authors and Affiliations

  1. Department of Hematology, University Medical Center Nijmegen, Nijmegen, The Netherlands

    M Smeets, R Raymakers, P Muus & T de Witte

  2. Central Laboratory of Hematology, University Medical Center Nijmegen, Nijmegen, The Netherlands

    G Vierwinden & P Linssen

  3. Department of Pharmacology and Toxicology, University Medical Center Nijmegen, Nijmegen, The Netherlands

    R Masereeuw

Authors
  1. M Smeets
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Raymakers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Muus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Vierwinden
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Linssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Masereeuw
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T de Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smeets, M., Raymakers, R., Muus, P. et al. Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance. Leukemia 15, 80–88 (2001). https://doi.org/10.1038/sj.leu.2401996

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401996

Keywords

This article is cited by

Search

Advanced search

Quick links